risperidone has been researched along with Hypertriglyceridemia in 5 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 7.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| "Schizophrenic patients treated with clozapine or olanzapine often develop hypertriglyceridemia." | 3.78 | Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment. ( Bai, YM; Chen, TT; Hong, CJ; Liou, YJ; Tsai, SJ, 2012) |
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 3.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| "Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2." | 1.32 | Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinbrenner, A | 1 |
| Peus, V | 1 |
| Inta, D | 1 |
| Englisch, S | 1 |
| Zink, M | 1 |
| Calarge, CA | 1 |
| Acion, L | 1 |
| Kuperman, S | 1 |
| Tansey, M | 1 |
| Schlechte, JA | 1 |
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Hamer, RM | 1 |
| Dunlop, BW | 1 |
| Hong, CJ | 1 |
| Chen, TT | 1 |
| Bai, YM | 1 |
| Liou, YJ | 1 |
| Tsai, SJ | 1 |
| Alméras, N | 1 |
| Després, JP | 1 |
| Villeneuve, J | 1 |
| Demers, MF | 1 |
| Roy, MA | 1 |
| Cadrin, C | 1 |
| Mottard, JP | 1 |
| Bouchard, RH | 1 |
5 other studies available for risperidone and Hypertriglyceridemia
| Article | Year |
|---|---|
Risperidone-associated increase in triglyceride levels.
Topics: Adult; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Humans; Hypercholesterol | 2009 |
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Child; Cholesterol, HDL; Drug Administration Sche | 2009 |
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Fema | 2009 |
Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Apolipoprotein A-V; Apolipoproteins A; Benzodiazepines; Clozapine; Fema | 2012 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary | 2004 |